In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii

Lett Appl Microbiol. 2020 Mar;70(3):189-195. doi: 10.1111/lam.13259. Epub 2019 Dec 29.

Abstract

The aim of this study was to investigate the in vitro interactions of ambroxol hydrochloride (ABH) or amlodipine (AML) with commonly used antibacterial agents, including meropenem, imipenem-cilastatin sodium, biapenem, cefoperazone-sulbactam, polymyxin B, and tigecycline, against six carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates. Drug interactions were interpreted using two models, that is, the fractional inhibitory concentration index (FICI) model and the percentage of growth difference (ΔE) model. The results show that a majority of the combination groups exhibited partial synergy and additive interactions, such as the combinations of carbapenems and cefoperazone-sulbactam (SCF) with ABH or AML. While the combination of PB/AML exhibited synergistic interactions against all tested isolates, and PB/ABH exhibited synergistic interactions against two isolates. The FICI and ΔE model correlated very well for the combinations of PBABH and PB/AML against AB2. The combinations of TGC with ABH or AML mainly exhibited additive and indifferent interactions. There were no antagonistic interactions observed in any of the combinations. In conclusion, this study revealed that the non-antibacterial agents ABH or AML can work synergistically or partial synergistically with antibacterial agents against CRAB. This finding is crucial for overcoming the carbapenem resistance of A. baumannii. SIGNIFICANCE AND IMPACT OF THE STUDY: Drug combination is an effective approach for the treatment of resistant bacterial infection. The significance of using drug combination is that it can reduce drug dosage requirements, reduce the toxic effects of agents and prevent or delay the emergence of drug resistance. This study measured the in vitro interactions between non-antimicrobial agents and antibacterial agents against carbapenem-resistant Acinetobacter baumannii and the results of this study provide new insight to find strategies to overcome the carbapenem resistance in A. baumannii.

Keywords: ambroxol hydrochloride; amlodipine; antibacterial agents; carbapenem-resistant Acinetobacter baumannii; synergy.

MeSH terms

  • Acinetobacter Infections / microbiology
  • Acinetobacter baumannii / drug effects*
  • Acinetobacter baumannii / genetics
  • Acinetobacter baumannii / growth & development
  • Ambroxol / pharmacology*
  • Amlodipine / pharmacology*
  • Anti-Bacterial Agents / pharmacology*
  • Carbapenems / pharmacology
  • Cefoperazone / pharmacology
  • Cilastatin, Imipenem Drug Combination / pharmacology
  • Drug Combinations
  • Drug Resistance, Bacterial / genetics*
  • Drug Synergism
  • Humans
  • Meropenem / pharmacology
  • Microbial Sensitivity Tests
  • Sulbactam / pharmacology
  • Thienamycins / pharmacology

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Drug Combinations
  • Thienamycins
  • Amlodipine
  • Ambroxol
  • Cefoperazone
  • Cilastatin, Imipenem Drug Combination
  • Meropenem
  • Sulbactam
  • biapenem